- Home
- VIR vs CVAC Comparison
VIR vs CVAC Comparison
Compare VIR & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIR
- CVAC
- Stock Information
- Founded
- VIR 2016
- CVAC 2000
- Country
- VIR United States
- CVAC Germany
- Employees
- VIR N/A
- CVAC N/A
- Industry
- VIR Biotechnology: Pharmaceutical Preparations
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- VIR Health Care
- CVAC Health Care
- Exchange
- VIR Nasdaq
- CVAC Nasdaq
- Market Cap
- VIR 844.9M
- CVAC 818.8M
- IPO Year
- VIR 2019
- CVAC 2020
- Fundamental
- Price
- VIR $5.41
- CVAC $3.59
- Analyst Decision
- VIR Strong Buy
- CVAC Strong Buy
- Analyst Count
- VIR 7
- CVAC 2
- Target Price
- VIR $33.57
- CVAC $14.00
- AVG Volume (30 Days)
- VIR 1.0M
- CVAC 527.9K
- Earning Date
- VIR 05-07-2025
- CVAC 05-22-2025
- Dividend Yield
- VIR N/A
- CVAC N/A
- EPS Growth
- VIR N/A
- CVAC N/A
- EPS
- VIR N/A
- CVAC 0.75
- Revenue
- VIR $20,861,000.00
- CVAC $554,073,921.00
- Revenue This Year
- VIR N/A
- CVAC N/A
- Revenue Next Year
- VIR $10.65
- CVAC $38.07
- P/E Ratio
- VIR N/A
- CVAC $4.66
- Revenue Growth
- VIR N/A
- CVAC 895.54
- 52 Week Low
- VIR $4.95
- CVAC $2.22
- 52 Week High
- VIR $14.45
- CVAC $5.28
- Technical
- Relative Strength Index (RSI)
- VIR 35.98
- CVAC 61.59
- Support Level
- VIR $5.83
- CVAC $3.26
- Resistance Level
- VIR $6.29
- CVAC $3.79
- Average True Range (ATR)
- VIR 0.31
- CVAC 0.21
- MACD
- VIR 0.02
- CVAC 0.02
- Stochastic Oscillator
- VIR 28.80
- CVAC 73.00
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
About CVAC CureVac N.V.
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.